Share on StockTwits

Cleveland BioLabs (NASDAQ:CBLI) was the target of a large growth in short interest during the month of June. As of June 13th, there was short interest totalling 731,037 shares, a growth of 31.2% from the May 30th total of 557,121 shares, American Banking and Market News reports. Based on an average daily trading volume, of 390,617 shares, the short-interest ratio is currently 1.9 days. Currently, 1.5% of the shares of the company are sold short.

Cleveland BioLabs (NASDAQ:CBLI) opened at 0.4733 on Thursday. Cleveland BioLabs has a one year low of $0.46 and a one year high of $1.84. The stock has a 50-day moving average of $0.53 and a 200-day moving average of $0.72. The company’s market cap is $24.1 million.

Cleveland BioLabs (NASDAQ:CBLI) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.03) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.02.

Cleveland BioLabs, Inc (NASDAQ:CBLI), incorporated on June 5 2003, is a biotechnology company focused on developing biodefense, tissue protection and cancer treatment drugs based on the concept of modulation of cell death for therapeutic benefit.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.